Generic Drugmaker Prevails in Supreme Court Patent Case

The U.S. Supreme Court unanimously ruled in favor of generic drugmaker Hikma, stating its version of a cardiovascular medication did not infringe on Amarin Pharma's patents. This decision could reduce the vulnerability of generic drug manufacturers to patent lawsuits involving 'skinny labels.' The outcome may also contribute to lower prescription drug prices.